A családi halmozódást mutató petefészek- és emlőrákok többségéért a BRCA1/2 gének mutációi felelősek. A rosszindulatú petefészek-daganatok hozzávetőleg 10%-a alakul ki a BRCA1/2 gének csíravonalbeli mutációja következtében. A daganatok többsége serosus és endometrioid szövettani típusú és rosszul differenciált. A mutációkat hordozó nők esetében a 40 éves életkor elérésekor vagy a családterv lezárásakor kockázatcsökkentő salpingo-oophorectomia javasolt. Napjainkban nincsen különbség a sporadikus és a herediter petefészekrákok kezelése között, bár a BRCA1/2 mutációk jelenlétekor a célzott terápia nagyobb hatékonyságát észlelték. A retrospektív tanulmányokban a mutációk fennállásakor a platinaszármazékokkal szemben érzékenyebbek voltak a daganatok, és a korai vizsgálatok szerint a mutációt hordozó, előrehaladott petefészekrákban szenvedők esetében hatékonyabb volt a poli-ADP-ribóz polimeráz gátlóival történő kezelés is. Ezeknek a szereknek a kemoprevencióban is szerepe lehet. Közleményünkben a családi halmozódású petefészekrák ellátásának elveit foglaljuk össze. Orv. Hetil., 2011, 152, 1596–1608.
World Health Organization: World Health Organization Statistics. 2008.
Risch, H. A., McLaughlin, J. R., Cole, D. E. C. és mtsai: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin cohort study in Ontario, Canada. J. Natl. Cancer Inst., 2006, 98, 1694–1706.
Cole D. E. C. , 'Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin cohort study in Ontario, Canada ' (2006 ) 98 J. Natl. Cancer Inst. : 1694 -1706 .
Drew, Y., Calvert, H.: The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann. N.Y. Acad. Sci., 2008, 1138, 136–145.
Calvert H. , 'The potential of PARP inhibitors in genetic breast and ovarian cancers ' (2008 ) 1138 Ann. N.Y. Acad. Sci. : 136 -145 .
Cook, J.: Family history of ovarian cancer. Curr. Obstet. Gynecol., 2002, 12, 47–51.
Cook J. , 'Family history of ovarian cancer ' (2002 ) 12 Curr. Obstet. Gynecol. : 47 -51 .
Malkin, D., Li, F. P., Strong, L. C. és mtsai: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science, 1990, 250, 1233–1238.
Strong L. C. , 'Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms ' (1990 ) 250 Science : 1233 -1238 .
Lynch, E. D., Ostermeyer, E. A., Lee, M. K. és mtsai: Inherited mutations in PTEN that are associated with breast cancer, Cowden disease and juvenile polyposis. Am. J. Hum. Genet., 1997, 61, 1254–1260.
Lee M. K. , 'Inherited mutations in PTEN that are associated with breast cancer, Cowden disease and juvenile polyposis ' (1997 ) 61 Am. J. Hum. Genet. : 1254 -1260 .
Renwick, A., Thompson, D., Seal, S. és mtsai: ATM mutations that cause ataxia teleangiectasia are breast cancer susceptibiltiy alleles. Nat. Genet., 2006, 38, 873–875.
Seal S. , 'ATM mutations that cause ataxia teleangiectasia are breast cancer susceptibiltiy alleles ' (2006 ) 38 Nat. Genet. : 873 -875 .
Giardello, F. M., Brensinger, J. D., Tersmette, A. C. és mtsai: Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology, 2000, 119, 1447–1453.
Tersmette A. C. , 'Very high risk of cancer in familial Peutz–Jeghers syndrome ' (2000 ) 119 Gastroenterology : 1447 -1453 .
Kasprzak, L., Foulkes, W. D., Shelling, A. N.: Hereditary ovarian carcinoma. Br. Med. J., 1999, 318, 786–789.
Shelling A. N. , 'Hereditary ovarian carcinoma ' (1999 ) 318 Br. Med. J. : 786 -789 .
Barroso, E., Milne, R. L., Fernandez, L. P. és mtsai: FANC2D associated with sporadic breast cancer. Carcinogenesis, 2006, 27, 1930–1937.
Fernandez L. P. , 'FANC2D associated with sporadic breast cancer ' (2006 ) 27 Carcinogenesis : 1930 -1937 .
Aarnio, M., Mecklin, J., Aaltonen, L. A. és mtsai: Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer, 1995, 64, 430–433.
Aaltonen L. A. , 'Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome ' (1995 ) 64 Int. J. Cancer : 430 -433 .
Quaye, L., Tyrer, J., Ramus, S. J. és mtsai: Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS One, 2009, 4, e5983, 1–7.
Ramus S. J. , 'Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer ' (2009 ) 4 PLoS One : 1 -7 .
Ramus, S. J., Vierkant, R. A., Johnatty, S. E. és mtsai: Consortium analysis of 7 candidate SNPs for ovarian cancer. Int. J. Cancer, 2008, 123, 380–388.
Johnatty S. E. , 'Consortium analysis of 7 candidate SNPs for ovarian cancer ' (2008 ) 123 Int. J. Cancer : 380 -388 .
Palmieri, R. T., Wilson, M. A., Iversen, E. S. és mtsai: Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 3567–3572.
Iversen E. S. , 'Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women ' (2008 ) 17 Cancer Epidemiol. Biomarkers Prev. : 3567 -3572 .
Shen, J., Ambrosone, C. B., DiCiccio, R. A. és mtsai: A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 2008, 29, 1963–1966.
DiCiccio R. A. , 'A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis ' (2008 ) 29 Carcinogenesis : 1963 -1966 .
Hoskins, K. F., Stopfer, J. E., Calzone, K. A. és mtsai: Assessment and counselling for women with a family history of breast cancer: a guide for clinicians. JAMA, 1995, 273, 577–585.
Calzone K. A. , 'Assessment and counselling for women with a family history of breast cancer: a guide for clinicians ' (1995 ) 273 JAMA : 577 -585 .
Olopade, O. I., Pichert, G.: Cancer genetics in oncology practice. Ann. Oncol., 2001, 12, 895–908.
Pichert G. , 'Cancer genetics in oncology practice ' (2001 ) 12 Ann. Oncol. : 895 -908 .
Hildreth, N. G., Kelsey, J. L., LiVolsi, V. A. és mtsai: An epidemiologic study of the epithelial ovarian cancer. Am. J. Epidemiol., 1981, 114, 398–405.
LiVolsi V. A. , 'An epidemiologic study of the epithelial ovarian cancer ' (1981 ) 114 Am. J. Epidemiol. : 398 -405 .
Mori, M., Harabuchi, I., Miyake, H. és mtsai: Reproductive, genetic and dietary risk factors for ovarian cancer. Am. J. Epidemiol., 1988, 128, 771–777.
Miyake H. , 'Reproductive, genetic and dietary risk factors for ovarian cancer ' (1988 ) 128 Am. J. Epidemiol. : 771 -777 .
Franceschi, S., Parazzini, F., Negri, E. és mtsai: Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int. J. Cancer, 1991, 49, 61–65.
Negri E. , 'Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use ' (1991 ) 49 Int. J. Cancer : 61 -65 .
Adami, H. O., Hsieh, C. C., Lambe, M. és mtsai: Parity, age at first childbirth, and risk of ovarian cancer. Lancet, 1994, 344, 1250–1254.
Lambe M. , 'Parity, age at first childbirth, and risk of ovarian cancer ' (1994 ) 344 Lancet : 1250 -1254 .
Parkin, D. M., Whelan, S. L., Ferlay, J. és mtsai: Cancer Incidence in Five Continents. Vol. VII. IARC Scientific Publications, Lyon, 1997.
Ferlay J. , '', in Cancer Incidence in Five Continents. Vol. VII , (1997 ) -.
Hartge, P., Whittemore, S., Itnyre, J. és mtsai: Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet. Gynecol., 1994, 84, 760–764.
Itnyre J. , 'Rates and risks of ovarian cancer in subgroups of white women in the United States ' (1994 ) 84 Obstet. Gynecol. : 760 -764 .
Schildkraut, J. M., Risch, N., Thompson, W. D. és mtsai: Evaluating genetic association among ovarian, breast and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am. J. Hum. Genet., 1989, 45, 521–529.
Thompson W. D. , 'Evaluating genetic association among ovarian, breast and endometrial cancer: evidence for a breast/ovarian cancer relationship ' (1989 ) 45 Am. J. Hum. Genet. : 521 -529 .
Houlston, R. S., Bourne, T. H., Collins, W. P. és mtasi: Risk of ovarian cancer and genetic relationship to other cancer families. Hum. Hered., 1993, 43, 111–115.
Collins W. P. , 'Risk of ovarian cancer and genetic relationship to other cancer families ' (1993 ) 43 Hum. Hered. : 111 -115 .
Moslehi, R., Chu, W., Karlan, B. és mtsai: BRCA1 and BRCA2 mutation analysis of 208 Askhenazi Jewish women with ovarian cancer. Am. J. Hum. Genet., 2000, 66, 1259–1272.
Karlan B. , 'BRCA1 and BRCA2 mutation analysis of 208 Askhenazi Jewish women with ovarian cancer ' (2000 ) 66 Am. J. Hum. Genet. : 1259 -1272 .
Jishi, M. F., Itnyre, J. H., Oakley-Girvan, I. A. és mtsai: Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer, 1995, 76, 1416–1421.
Oakley-Girvan I. A. , 'Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry ' (1995 ) 76 Cancer : 1416 -1421 .
Liber, A. F.: Ovarian cancer in a mother and five daughters. Arch. Pathol., 1950, 49, 280–290.
Liber A. F. , 'Ovarian cancer in a mother and five daughters ' (1950 ) 49 Arch. Pathol. : 280 -290 .
Go, R. C., King, M. C., Bailey-Wilson, J. és mtsai: Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregeation analysis. J. Natl. Cancer Inst., 1983, 71, 455–461.
Bailey-Wilson J. , 'Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregeation analysis ' (1983 ) 71 J. Natl. Cancer Inst. : 455 -461 .
Miki, Y., Swensen, J., Shattuck-Eidens, D. és mtsai: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994, 266, 66–71.
Shattuck-Eidens D. , 'A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 ' (1994 ) 266 Science : 66 -71 .
Wooster, R., Bignell, G., Lancaster, J. és mtsai: Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378, 789–792.
Lancaster J. , 'Identification of the breast cancer susceptibility gene BRCA2 ' (1995 ) 378 Nature : 789 -792 .
Roth, S., Kristo, P., Auranen, A. és mtsai: A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. Br. J. Cancer, 1998, 77, 1199–1202.
Auranen A. , 'A missense mutation in the BRCA2 gene in three siblings with ovarian cancer ' (1998 ) 77 Br. J. Cancer : 1199 -1202 .
Vasen, H. F., Mecklin, J. P., Khan, P. M. és mtsai: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum, 1991, 34, 424–425.
Khan P. M. , 'The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) ' (1991 ) 34 Dis. Colon Rectum : 424 -425 .
Russo, A., Calo, V., Bruno, I. és mtsai: Hereditary ovarian cancer. Crit. Rev. Oncol. Hematol., 2009, 69, 28–44.
Bruno I. , 'Hereditary ovarian cancer ' (2009 ) 69 Crit. Rev. Oncol. Hematol. : 28 -44 .
Lancaster, J. M., Powell, C. B., Kauff, N. D. és mtsai: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol., 2007, 107, 159–162.
Kauff N. D. , 'Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions ' (2007 ) 107 Gynecol. Oncol. : 159 -162 .
Buermeyer, A. B., Deschenes, S. M., Baker, S. M. és mtsai: Mammalian DNA mismatch repair. Annu. Rev. Genet., 1999, 33, 533–564.
Baker S. M. , 'Mammalian DNA mismatch repair ' (1999 ) 33 Annu. Rev. Genet. : 533 -564 .
Bewtra, C., Watson, P., Conway, T. és mtsai: Hereditary ovarian cancer: a clinicopathological study. Int. J. Gynecol. Pathol., 1992, 11, 180–187.
Conway T. , 'Hereditary ovarian cancer: a clinicopathological study ' (1992 ) 11 Int. J. Gynecol. Pathol. : 180 -187 .
Muto, M. G., Cramer, D. W., Tangir, J. és mtsai: Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res., 1996, 56, 1250–1252.
Tangir J. , 'Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls ' (1996 ) 56 Cancer Res. : 1250 -1252 .
Tonin, P. M., Mes-Masson, A. M., Narod, S. A. és mtsai: Founder BRCA1 and BRCA2 mutations in French-Canadian ovarian cancer cases unselected for family history. Clin. Genet., 1999, 55, 318–324.
Narod S. A. , 'Founder BRCA1 and BRCA2 mutations in French-Canadian ovarian cancer cases unselected for family history ' (1999 ) 55 Clin. Genet. : 318 -324 .
Mæhle, L., Apold, J., Paulsen, T. és mtsai: High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin. Canc. Res., 2008, 14, 7569–7573.
Paulsen T. , 'High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers ' (2008 ) 14 Clin. Canc. Res. : 7569 -7573 .
Piver, M. S., Baker, T. R., Jishi, M. F. és mtsai: Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer, 1993, 71, 582–588.
Jishi M. F. , 'Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991 ' (1993 ) 71 Cancer : 582 -588 .
Lakhani, S. R., Manek, S., Penault-Llorca, F. és mtsai: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Canc. Res., 2004, 10, 2473–2481.
Penault-Llorca F. , 'Pathology of ovarian cancers in BRCA1 and BRCA2 carriers ' (2004 ) 10 Clin. Canc. Res. : 2473 -2481 .
Fathalla, M. F.: Incessant ovulation – a factor in ovarian neoplasia? Lancet, 1971, 2, 163.
Fathalla M. F. , 'Incessant ovulation – a factor in ovarian neoplasia? ' (1971 ) 2 Lancet : 163 -.
Rubin, C., Benjamin, I., Behbakht, K. és mtsai: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA. N. Engl. J. Med., 1996, 335, 1413–1416.
Behbakht K. , 'Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA ' (1996 ) 335 N. Engl. J. Med. : 1413 -1416 .
Piver, M. S.: Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial 64. Ovarian Cancer Registry. Gynecol. Oncol., 2002, 85, 9–17.
Piver M. S. , 'Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial 64. Ovarian Cancer Registry ' (2002 ) 85 Gynecol. Oncol. : 9 -17 .
Teneriello, M., Park, R. C.: Early detection of ovarian cancer. CA Cancer J. Clin., 1995, 45, 71–87.
Park R. C. , 'Early detection of ovarian cancer ' (1995 ) 45 CA Cancer J. Clin. : 71 -87 .
Nguyen, N. H., Averette, H. E., Hoskins, W. és mtsai: Natural survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Obstetrics and Gynecology Staging system. Cancer, 1993, 72, 3007–3011.
Hoskins W. , 'Natural survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Obstetrics and Gynecology Staging system ' (1993 ) 72 Cancer : 3007 -3011 .
Karlan, B. Y., Baldwin, R. L., Lopez-Luevanos, E. és mtsai: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am. J. Obstet. Gynecol., 1999, 180, 917–928.
Lopez-Luevanos E. , 'Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening ' (1999 ) 180 Am. J. Obstet. Gynecol. : 917 -928 .
Bell, R., Luengo, S., Petticrew, M. és mtsai: Screening for ovarian cancer: a systematic review. Health Technol. Assess., 1998, 2, 1–84.
Petticrew M. , 'Screening for ovarian cancer: a systematic review ' (1998 ) 2 Health Technol. Assess. : 1 -84 .
Jacobs, I., Oram, D.: Screening for ovarian cancer. Biomed. Pharmacother., 1988, 42, 589–596.
Oram D. , 'Screening for ovarian cancer ' (1988 ) 42 Biomed. Pharmacother. : 589 -596 .
Van Nagel, J. R. Jr., Gallion, H. H., Pavlik, E. J. és mtsa: Ovarian cancer screening. Cancer, 1995, 76, (10 Suppl.), 2086–2091.
Pavlik E. J. , 'Ovarian cancer screening ' (1995 ) 76 Cancer : 2086 -2091 .
Van Nagel, J. R. Jr., DePriest, P. D., Reedy, M. B. és mtsai: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol., 2000, 77, 350–356.
Reedy M. B. , 'The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer ' (2000 ) 77 Gynecol. Oncol. : 350 -356 .
Pavlik, E. J., DePriest, P. D., Gallion, H. H. és mtsai: Ovarian volume related to age. Gynecol. Oncol., 2000, 77, 410–412.
Gallion H. H. , 'Ovarian volume related to age ' (2000 ) 77 Gynecol. Oncol. : 410 -412 .
DePriest, P. D., Varner, E., Powell, J. és mtsai: The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol. Oncol., 1994, 55, 174–178.
Powell J. , 'The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation ' (1994 ) 55 Gynecol. Oncol. : 174 -178 .
Carter, J. R., Lau, M., Fowler, J. M. és mtsai: Blood flow characteristics of ovarian tumours: implications for early detection for ovarian cancer screening. Am. J. Obstet. Gynecol., 1995, 72, 901–907.
Fowler J. M. , 'Blood flow characteristics of ovarian tumours: implications for early detection for ovarian cancer screening ' (1995 ) 72 Am. J. Obstet. Gynecol. : 901 -907 .
Predanic, M., Vlahos, N., Pennisi, J. A. és mtsai: Color and pulsed Doppler sonography, grey-scale imaging and serum CA 125 in the assessment of adnexal disease. Obstet. Gynecol., 1996, 88, 283–288.
Pennisi J. A. , 'Color and pulsed Doppler sonography, grey-scale imaging and serum CA 125 in the assessment of adnexal disease ' (1996 ) 88 Obstet. Gynecol. : 283 -288 .
Bourne, T. H., Campbell, S., Reynolds, K. M. és mtsai: Screening for early ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br. Med. J., 1993, 306, 1025–1029.
Reynolds K. M. , 'Screening for early ovarian cancer with transvaginal ultrasonography and colour blood flow imaging ' (1993 ) 306 Br. Med. J. : 1025 -1029 .
Campbell, S., Bhan, V., Royston, P. és mtsai: Transabdominal ultrasound screening for ovarian cancer. Br. Med. J., 1989, 299, 1363–1367.
Royston P. , 'Transabdominal ultrasound screening for ovarian cancer ' (1989 ) 299 Br. Med. J. : 1363 -1367 .
Bast, R., Klug, T. L., St. John, E. és mtsai: Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest., 1981, 68, 1331–1337.
John E. , 'Reactivity of a monoclonal antibody with human ovarian carcinoma ' (1981 ) 68 J. Clin. Invest. : 1331 -1337 .
Zurawski, V., Orjaseter, H., Andersen, A. és mtsai: Elevated serum CA-125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer, 1988, 42, 677–680.
Andersen A. , 'Elevated serum CA-125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer ' (1988 ) 42 Int. J. Cancer : 677 -680 .
Jacobs, I., Bast, R. C. Jr.: The CA-125 tumour-associated antigen: a review of the literature. Hum. Reprod., 1989, 4, 1–12.
Bast R. C. , 'The CA-125 tumour-associated antigen: a review of the literature ' (1989 ) 4 Hum. Reprod. : 1 -12 .
Medeiros, L. R., Dornelles Rosa, D., da Rosa, M. I. és mtsai: Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 142, 99–105.
Rosa M. I. , 'Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review ' (2009 ) 142 Eur. J. Obstet. Gynecol. Reprod. Biol. : 99 -105 .
Skates, S. J., Xu, F. J., Yu, Y. H. és mtsai: Toward an optimal algorhythm for ovarian cancer screening with longitudinal tumor markers. Cancer, 1995, 76, (10 Suppl.), 2004–2010.
Yu Y. H. , 'Toward an optimal algorhythm for ovarian cancer screening with longitudinal tumor markers ' (1995 ) 76 Cancer : 2004 -2010 .
Moore, R. G., MacLaughlan, S., Bast, R. C. Jr.: Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol. Oncol., 2010, 116, 240–245.
Bast R. C. , 'Current state of biomarker development for clinical application in epithelial ovarian cancer ' (2010 ) 116 Gynecol. Oncol. : 240 -245 .
Frank, T. S., Manley, S. A., Olopade, O. I. és mtsai: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol., 1998, 16, 2417–2425.
Olopade O. I. , 'Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk ' (1998 ) 16 J. Clin. Oncol. : 2417 -2425 .
Wakahara, F., Kikkawa, F., Nawa, A. és mtsai: Diagnostic efficacy of tumor markers, sonography and intraoperative frozen section for ovarian tumors. Gyn. Obstet. Invest., 2001, 52, 147–152.
Nawa A. , 'Diagnostic efficacy of tumor markers, sonography and intraoperative frozen section for ovarian tumors ' (2001 ) 52 Gyn. Obstet. Invest. : 147 -152 .
Despierre, E., Lambrechts, D., Neven, P. és mtsai: The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol. Oncol., 2010, 117, 358–365.
Neven P. , 'The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment ' (2010 ) 117 Gynecol. Oncol. : 358 -365 .
Hall, J., Paul, J., Brown, R.: Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev. Mol. Med., 2004, 6, 1–20.
Brown R. , 'Critical evaluation of p53 as a prognostic marker in ovarian cancer ' (2004 ) 6 Expert Rev. Mol. Med. : 1 -20 .
Obata, K., Morland, S. J., Watson, R. H. és mtsai: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 1998, 58, 2095–2097.
Watson R. H. , 'Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors ' (1998 ) 58 Cancer Res. : 2095 -2097 .
Kurman, R. J., Shih, I. M.: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol., 2008, 27, 151–160.
Shih I. M. , 'Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications ' (2008 ) 27 Int. J. Gynecol. Pathol. : 151 -160 .
Singer, G., Stöhr, R., Cope, L. és mtsai: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol., 2005, 29, 218–224.
Cope L. , 'Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation ' (2005 ) 29 Am. J. Surg. Pathol. : 218 -224 .
Barton, C. A., Hacker, N. F., Clark, S. J. és mtsai: DNA methylation changes in ovarian cancer: implication for early diagnosis, prognosis and treatment. Gynecol. Oncol., 2008, 109, 129–139.
Clark S. J. , 'DNA methylation changes in ovarian cancer: implication for early diagnosis, prognosis and treatment ' (2008 ) 109 Gynecol. Oncol. : 129 -139 .
Couzin, J.: MicroRNAs make big impression in disease after disease. Science, 2008, 319, 1782–1784.
Couzin J. , 'MicroRNAs make big impression in disease after disease ' (2008 ) 319 Science : 1782 -1784 .
Zhang, L., Huang, J., Yang, N. és mtsai: MicroRNAs exhibit high frequency genomic alterations in human cancers. Proc. Natl. Acad. Sci. USA, 2008, 105, 13021–13026.
Yang N. , 'MicroRNAs exhibit high frequency genomic alterations in human cancers ' (2008 ) 105 Proc. Natl. Acad. Sci. USA : 13021 -13026 .
Quinn, J. E., Carser, J. E., James, C. R. és mtsai: BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol. Oncol., 2009, 113, 134–142.
James C. R. , 'BRCA1 and implications for response to chemotherapy in ovarian cancer ' (2009 ) 113 Gynecol. Oncol. : 134 -142 .
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y. és mtsai: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol., 2010, 28, 3555–3561. Erratum in: J. Clin. Oncol., 2010, 28, 4868.
Karlan B. Y. , 'Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer ' (2010 ) 28 J. Clin. Oncol. : 3555 -3561 .